Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor
Advertisement
GlaxoSmithKline plc (GSK) and elbion AG announce that they have signed a worldwide agreement to collaborate on the development and commercialisation of elbion's phosphodiesterase (PDE) IV inhibitor, AWD 12-281 and associated back-up compounds. AWD 12-281 is currently in phase II clinical studies by the intra nasal delivery route for allergic rhinitis and phase I studies by inhaled delivery for asthma and chronic obstructive pulmonary disease (COPD).
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
InterMed Discovery achieves Proof-of-Principle for IMD-026260 - Small molecule anti-cancer drug candidate based on Hif-1 modulation
Large international study finds memory in adults impacted by versions of 4 genes - Second study identifies brain-development genes associated with intracranial volume
Evolva acquires resveratrol programme from Fluxome
Network that plays crucial role in cell function and disease
Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test